دورية أكاديمية
Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis.
| العنوان: | Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis. |
|---|---|
| المؤلفون: | Vochoskova K; National Institute of Mental Health, Klecany, Czech Republic.; Third Faculty of Medicine, Charles University, Prague, Czech Republic., McWhinney SR; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada., Fialova M; National Institute of Mental Health, Klecany, Czech Republic.; Third Faculty of Medicine, Charles University, Prague, Czech Republic., Kolenic M; National Institute of Mental Health, Klecany, Czech Republic.; Third Faculty of Medicine, Charles University, Prague, Czech Republic., Spaniel F; National Institute of Mental Health, Klecany, Czech Republic.; Third Faculty of Medicine, Charles University, Prague, Czech Republic., Furstova P; National Institute of Mental Health, Klecany, Czech Republic., Boron P; Psychiatric Hospital Bohnice, Prague, Czech Republic., Okaji Y; Psychiatric Hospital Bohnice, Prague, Czech Republic., Trancik P; Psychiatric Hospital Bohnice, Prague, Czech Republic., Hajek T; National Institute of Mental Health, Klecany, Czech Republic.; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada. |
| المصدر: | European psychiatry : the journal of the Association of European Psychiatrists [Eur Psychiatry] 2024 Sep 26; Vol. 67 (1), pp. e59. Date of Electronic Publication: 2024 Sep 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cambridge University Press Country of Publication: England NLM ID: 9111820 Publication Model: Electronic Cited Medium: Internet ISSN: 1778-3585 (Electronic) Linking ISSN: 09249338 NLM ISO Abbreviation: Eur Psychiatry Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : Cambridge : Cambridge University Press Original Publication: Paris : Editions scientifiques Elsevier, c1991- |
| مواضيع طبية MeSH: | Antipsychotic Agents*/therapeutic use , Antipsychotic Agents*/adverse effects , Weight Gain*/drug effects , Psychotic Disorders*/drug therapy , Hospitalization*/statistics & numerical data , Body Mass Index* , Schizophrenia*/drug therapy, Humans ; Female ; Male ; Adult ; Young Adult ; Risperidone/therapeutic use ; Risperidone/adverse effects ; Olanzapine/therapeutic use ; Polypharmacy ; Prospective Studies ; Risk Factors |
| مستخلص: | Background: We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia. Methods: We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors. Results: Most people started treatment with risperidone ( n = 57), followed by olanzapine ( n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications. Conclusions: Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect. |
| معلومات مُعتمدة: | NV16-32791A Ministerstvo Zdravotnictví Ceské Republiky |
| فهرسة مساهمة: | Keywords: antipsychotics; polypharmacy; predictor; schizophrenia; weight gain |
| المشرفين على المادة: | 0 (Antipsychotic Agents) L6UH7ZF8HC (Risperidone) N7U69T4SZR (Olanzapine) |
| تواريخ الأحداث: | Date Created: 20240926 Date Completed: 20240926 Latest Revision: 20240926 |
| رمز التحديث: | 20240926 |
| DOI: | 10.1192/j.eurpsy.2024.1761 |
| PMID: | 39323217 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1778-3585 |
|---|---|
| DOI: | 10.1192/j.eurpsy.2024.1761 |